Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Johnson & Johnson (NYSE: JNJ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large New Jersey–incorporated healthcare issuer with common stock and multiple series of notes listed on the New York Stock Exchange, Johnson & Johnson reports material events, financial results and capital structure details through forms such as 10-K, 10-Q and 8-K.
Recent Form 8-K filings illustrate how Johnson & Johnson uses current reports to communicate key developments. For example, the company has filed 8-Ks to announce quarterly sales and earnings results for specific fiscal quarters, and to disclose its intent to separate its Orthopaedics business. These filings also list the securities registered under Section 12(b) of the Exchange Act, including the JNJ common stock and various notes with maturities extending from the late 2020s through the 2050s, each with its own NYSE trading symbol.
On this page, users can review Johnson & Johnson’s periodic reports for detailed information on its Innovative Medicine and MedTech operations, risk factors, research and development spending, and manufacturing and investment plans. Annual reports on Form 10-K and quarterly reports on Form 10-Q provide management’s discussion and analysis, segment information and notes to the financial statements, while current reports on Form 8-K highlight specific corporate actions, clinical or regulatory milestones and financing activities as they occur.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand topics such as revenue drivers, major therapeutic areas, MedTech initiatives, capital allocation decisions and announced business changes like the planned Orthopaedics separation. The platform also surfaces relevant items related to Johnson & Johnson’s registered debt securities and any disclosed board or governance actions. For investors, analysts and researchers, this page offers a structured view of Johnson & Johnson’s regulatory record, with real-time updates as new filings are posted to EDGAR.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These DSUs are to be settled in cash when his directorship ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date.
After this award, Woods holds a total of 6,215.094 DSUs, including dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividend. The transaction reflects compensation in the form of deferred, cash-settled, share-linked units rather than an open-market stock purchase or sale.
Johnson & Johnson director Nadja West received a grant of 975 Deferred Share Units (DSUs) on April 23, 2026. These DSUs were acquired under the company’s Amended and Restated Deferred Fee Plan for Directors at a price of $0.00 per unit.
Following this award, West holds a total of 7,730.0491 DSUs. Each DSU will be settled in cash upon the end of her board service, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holding also includes dividend equivalent rights that accrue as the company pays its quarterly dividend.
Johnson & Johnson director Mark A. Weinberger received a grant of 975 Deferred Share Units (DSUs) on Common Stock, reported as a compensation-related acquisition at a price of $0.00 per unit. After this grant, he holds a total of 12,010.408 DSUs directly.
According to the plan terms, these DSUs are to be settled in cash when his service as a director ends, with each DSU valued at the fair market value of one share of Common Stock on the settlement date. The reported holdings also include dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividend.
Pinto Daniel E reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Daniel E. Pinto received a grant of 1,712 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors and are a form of non-cash director compensation.
After this grant, Pinto holds a total of 2,174.069 DSUs. According to the disclosure, these DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The total also reflects dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividends.
Johnson & Johnson director John G. Morikis received a grant of 1,540 Deferred Share Units (DSUs) as compensation. These DSUs were acquired at a stated price of $0.00 per unit and are tied to Johnson & Johnson common stock for value reference.
According to the plan terms, the DSUs will be settled in cash after Morikis’ service as a director ends, with each unit worth the fair market value of one share of common stock on the settlement date. After this grant, he holds 1,540 DSUs related to this plan.
McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Mark B. McClellan received a grant of 975 Deferred Share Units (DSUs) tied to the company’s common stock. These DSUs were awarded under the Amended and Restated Deferred Fee Plan for Directors and increase his direct DSU holdings to 21,278.593 units.
The DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one Johnson & Johnson common share on the settlement date. The award also includes dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.
Joly Hubert reported acquisition or exercise transactions in this Form 4 filing.
JOHNSON & JOHNSON director Hubert Joly received a new equity-based award. On this Form 4, he was granted 975 Deferred Share Units (DSUs) tied to Johnson & Johnson common stock, increasing his DSU holdings to 9,183.605 units.
The DSUs were awarded at a stated price of $0.00 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. According to the disclosure, these DSUs will be settled in cash when Joly’s board service ends, with each DSU representing the fair market value of one share of common stock on the settlement date and including dividend equivalent rights that accrue with the company’s quarterly dividends.
Johnson Paula A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Paula A. Johnson received a grant of 975 Deferred Share Units (DSUs) tied to the company’s common stock. These DSUs were awarded at no cash cost and will be settled in cash when her board service ends, based on the then-current share value.
After this grant and related dividend-equivalent accruals, she holds a total of 5,359.3973 DSUs, which track the value of Johnson & Johnson common stock but do not involve immediate share purchases or sales.
HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Marillyn A. Hewson received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. The DSUs were awarded at $0.00 per unit and are classified as derivative securities.
After this grant, Hewson holds a total of 15,487.939 DSUs. According to the plan terms, these DSUs will be settled in cash when her service as a director ends, with each DSU representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.
Doudna Jennifer A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Jennifer A. Doudna received a grant of 975 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors.
The DSUs are to be settled in cash when her board service ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date. Following this grant, she holds a total of 10,899.1714 DSUs, including units attributable to dividend equivalent rights that accrue in connection with the company’s quarterly dividend.